

AroCell initiates a discussion with a new business partner

AroCells inform today that they have initiated a discussion with Attana AB about a collaboration.

Attana is an analytical instrument company within life science and has a broad customer base with many years of experience in quality and product development for *in vitro* diagnostics (IVD) and pharmaceutical companies. Based on the patented technology, the company sells self-produced analytical instruments. Attana has recently expanded its operations by starting a new business area within *in vitro* diagnostics. The collaboration aims to give AroCell access to Attana's extensive knowledge in quality and product development, while AroCell's biomarkers could eventually be used on Attana's instruments.

"We are pleased to be able to inform that discussions with Attana are ongoing. Attana is a very interesting partner that could support us both in quality assurance of the production and product development." says Anders Hultman, AroCell's CEO, and continues, "The opportunity to analyze our biomarkers for IVD customers on Attana's instruments is also a very interesting way forward."

"AroCell's long experience in the diagnostics market can help us on the path to growth in new parts of the diagnostics market. The collaboration is an important step in our strategy to establish Attana's technology as a platform in *in vitro* diagnostics. In addition, we already have good relations with AroCell, which means that we see that the collaboration can start quickly." says Teodor Aastrup, founder and CEO of Attana.

Contacts

Anders Hultman, CEO
Phone: +46(0)18 50 30 20
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare and established in various markets. In oncology, AroCell uses various biomarkers, TK1 and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Press Release
09 February 2022 10:20:00 CET



Attachments

[AroCell initiates a discussion with a new business partner](#)